Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Genitourinary 6Sarcoma 5Gastrointestinal 3Other solid neoplasm 2Other hematologic neoplasm 2Myeloid 2Dermatologic 2CNS 2Thoracic 1Gynecologic 1

Conditions

Solid Tumor 1Hepatic Impairment 1

Interventions

pembrolizumab 33Injections 28Pemetrexed 15Interviews as Topic 15Carboplatin 14tislelizumab 13Cisplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tazemetostat × Other solid neoplasm × 90 days × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health-Upstate

Phase 2 Terminated
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡